ANGPTL3 Genotype

Some people sail through life with naturally low triglycerides and cholesterol without trying. A rare reason is that they inherited a broken copy of the ANGPTL3 gene, which would otherwise tell the liver to make a protein that holds back fat-clearing enzymes in the blood.

This test reads your version of that gene. The result is permanent and tells you whether you carry a variant linked to a lifelong lipid profile that is unusually friendly to your arteries, or the more common version that does not offer that protection.

What ANGPTL3 Actually Does

ANGPTL3 (angiopoietin-like 3) is a protein made almost entirely by the liver and released into the bloodstream. Its job is to block two enzymes (lipoprotein lipase and endothelial lipase) that pull triglycerides and other fats out of circulation. When ANGPTL3 is doing more work, blood fats stay higher for longer. When the gene is partially broken and less ANGPTL3 is made, those fat-clearing enzymes run more freely, and triglycerides, LDL cholesterol, and HDL cholesterol all settle at lower lifelong levels.

Rare loss-of-function variants in ANGPTL3 cause a condition called familial combined hypolipidemia, marked by extremely low plasma levels of LDL cholesterol, HDL cholesterol, and triglycerides. Carrying two broken copies has more than four times the lipid-lowering effect of carrying one, so even one copy nudges your lipids in a favorable direction. A specific frameshift variant (p.Asn121fs) is one of the main drivers of low ANGPTL3 in carriers.

Heart Attack and Stroke Risk

This is the most consequential reason to know your ANGPTL3 genotype. Lifelong low ANGPTL3 activity from genetic variants tracks with a strikingly lower risk of coronary artery disease.

In the DiscovEHR cohort of more than 58,000 sequenced adults, carriers of loss-of-function ANGPTL3 variants had about 41% lower odds of coronary artery disease (adjusted odds ratio 0.59, 95% confidence interval 0.41 to 0.85). A meta-analysis combining DiscovEHR with four additional population studies put the overall reduction at about 39% (odds ratio 0.61, 95% confidence interval 0.45 to 0.81). A separate analysis of roughly 180,000 participants found carriers had about 34% lower odds of coronary artery disease (odds ratio 0.66, 95% confidence interval 0.44 to 0.98). A review of this same body of work places the protective effect against atherosclerotic cardiovascular disease at roughly 40%. In three individuals with complete ANGPTL3 deficiency, imaging found no coronary atherosclerotic plaque at all.

A common, non-rare variant called rs11207997 tells a milder version of the same story. People carrying the T allele, particularly TT homozygotes, had lower triglyceride and total cholesterol levels and a lower 10-year risk of diabetes in a Korean cohort of 7,358 adults. Other research links DOCK7-ANGPTL3 variants to coronary artery disease and ischemic stroke risk in a Southern Chinese Han population of 1,728 people.

What this means for you: if you carry a protective ANGPTL3 variant, you have inherited a head start against heart disease that a standard cholesterol panel does not explain. If you do not, your cardiovascular risk is set by everything else, and the standard levers (lipids, blood pressure, glucose, lifestyle) become the things you can actually move.

Liver Fat, Kidneys, and Diabetes

A reasonable worry about any genetic cause of very low cholesterol is whether fat builds up in the liver instead. The evidence here is reassuring. In a study of 130 people, those with ANGPTL3 deficiency from loss-of-function mutations did not show higher liver fat or worse fatty liver disease on imaging, and Mendelian randomization analyses of genetically lower ANGPTL3 reach the same conclusion.

Genetic mimicry of ANGPTL3 inhibition has also been linked to better kidney function and a lower risk of chronic kidney disease in a meta-analysis of lipid-modifying drug-target genes. The rs11207997 T allele in ANGPTL3 was associated with a lower risk of diabetes in the Korean cohort above.

When the Genetics and the Lipid Panel Disagree

There is a tension in the data worth resolving directly. Rare, lifelong loss-of-function variants clearly lower coronary artery disease risk. Drug-target Mendelian randomization using common variants that nudge ANGPTL3 levels only modestly shows strong triglyceride lowering but little or no effect on coronary artery disease. Meanwhile, a meta-analysis of protein-truncating variants confirms ANGPTL3 inactivation protects against coronary artery disease.

These findings are consistent once you see ANGPTL3 as a dose-response system. Mild, lifelong reductions in ANGPTL3 produce small lipid changes that may not be enough to bend the curve on heart disease risk. Substantial, lifelong reductions, the kind seen in loss-of-function carriers, do. The genotype matters because it tells you which end of that spectrum you are on.

One-Time Result, Lifetime of Decisions

Your ANGPTL3 genotype is fixed. It was set at conception and does not change with age, diet, weight, or medication. There is no value in retesting the gene itself unless the original result is unclear or you want to confirm a rare variant with a different method, such as Sanger sequencing after a chip-based call.

What does benefit from regular tracking is the downstream phenotype: lipids and inflammatory markers. If you carry a protective ANGPTL3 variant, an annual lipid panel and apoB still tell you whether your overall risk profile is as favorable as your genetics suggest. If you do not carry a protective variant and have a family history of early heart disease or borderline lipid numbers, more frequent lipid and apoB testing (every 3 to 6 months while making changes, then yearly) is the action item.

When Results Can Be Misleading

Genetic tests have their own set of confounders, different from blood biomarkers.

• Variant panel coverage: this test only detects the specific variants it is designed to read. A result that comes back without a known protective variant does not rule out other rare ANGPTL3 changes that the assay was not built to find.
• Ancestry: most ANGPTL3 genetic studies have been done in people of European ancestry. The frequency and clinical meaning of specific variants in other populations is less well characterized, including in Taiwanese Chinese, Iranian, Danish, Dutch, and Pakistani cohorts studied so far.
• Variants of uncertain significance: an unexpected ANGPTL3 change may be reported with unclear meaning. These calls usually need expert interpretation before they change anything you do.
• Clinical-grade versus consumer chips: a result from a direct-to-consumer genotyping service is not the same as a clinical sequencing panel. If a consumer test flags an ANGPTL3 variant, a clinical-grade test is the way to confirm it.

What To Do With An Unexpected Result

If you carry an ANGPTL3 loss-of-function variant, you have inherited a favorable lipid setting and a lower lifetime risk of coronary artery disease. The decision pathway is not to retest the gene but to integrate the finding: get a current lipid panel and apoB to confirm your phenotype matches, keep tracking those numbers annually, and tell biological family members, since they may share the variant and the protection.

If you do not carry a protective variant but your lipids look unusually low, that combination raises the question of whether another gene is responsible. Clinical workups for primary hypocholesterolemia typically sequence APOB first, then SAR1B, ANGPTL3, and MTTP. A specialist in lipidology or medical genetics is the right person to interpret that pathway.

If you do not carry a protective variant and you have a family history of early heart attacks or stroke, your lipid and apoB numbers carry more weight, not less. More frequent monitoring and earlier intervention thresholds become the path forward, since the genetic head start is not available to you.

What This Test Does Not Tell You

ANGPTL3 genotype is one piece of inherited cardiovascular risk, not the whole picture. It says nothing about Lp(a), APOE, or familial hypercholesterolemia variants, all of which are tested separately. It also does not measure your current ANGPTL3 protein level in blood, which can move with metabolic state and is a different assay. The genetic result is your lifetime setting; the protein level is your current state.